Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838708 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus
A Phase 2 study of Pruritus, Atopic Dermatitis, sponsored by Serentis.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 13
- Study locations
NCT00838708: Completed Phase 2 study of Pruritus, Atopic Dermatitis, sponsored by Serentis.
NCT00838708 is a Phase 2 study of Pruritus, Atopic Dermatitis that has completed, run by Serentis. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00838708, a Phase 2 study of Pruritus, Atopic Dermatitis, has completed, sponsored by Serentis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 13
- Study locations
Study Summary
Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time itching leading to sleep disturbance and subsequent poor daytime performance. The objective of this study is to determine whether SRD174 Cream is a safe and effective therapy for moderate to severe pruritus associated with atopic dermatitis.
Conditions Studied
Interventions
- DRUG SRD174 Cream
- OTHER vehicle cream
Study Locations (13)
Michigan
- - Detroit
- - Grand Blanc
North Carolina
- - High Point
- - Winston-Salem
Pennsylvania
- - Hazleton
- - Philadelphia
Alabama
- - Birmingham
Arkansas
- - Hot Springs
California
- - Oceanside
Florida
- - Ormond Beach
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00838708 record still lists
NCT00838708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Pruritus, Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which SRD174 Cream is the first listed.
NCT00838708 lists 13 locations in 10 states (Michigan, North Carolina, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00838708 about?
NCT00838708 is a clinical study titled "Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus". Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time itching leading to sleep disturbance and subsequent poor daytime performanc...
What is the current status of trial NCT00838708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2009-01. Estimated completion is 2009-08.
What conditions does trial NCT00838708 study?
This clinical trial studies the following conditions: Pruritus, Atopic Dermatitis.
What interventions are being tested in trial NCT00838708?
The interventions under investigation include: SRD174 Cream (DRUG), vehicle cream (OTHER).
Who is sponsoring clinical trial NCT00838708?
This trial is sponsored by Serentis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00838708 being conducted?
This trial has 13 study locations across Alabama, Arkansas, California, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00838708's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia